Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel.

Patel AR, Chougule MB, I T, Patlolla R, Wang G, Singh M.

Pharm Res. 2013 May;30(5):1435-46. doi: 10.1007/s11095-013-0984-9. Epub 2013 Jan 30.

2.

Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.

Fulzele SV, Chatterjee A, Shaik MS, Jackson T, Singh M.

Pharm Res. 2006 Sep;23(9):2094-106. Epub 2006 Aug 11.

3.

Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.

Fulzele SV, Shaik MS, Chatterjee A, Singh M.

J Pharm Pharmacol. 2006 Mar;58(3):327-36.

PMID:
16536899
4.

Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers.

Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PN, Singh M.

J Control Release. 2010 Jun 1;144(2):233-41. doi: 10.1016/j.jconrel.2010.02.006. Epub 2010 Feb 11.

5.

Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer.

Haynes A, Shaik MS, Chatterjee A, Singh M.

Pharm Res. 2005 Mar;22(3):427-39.

PMID:
15835749
6.

Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.

Zhang H, Li Z, Wang K.

Oncol Rep. 2014 Apr;31(4):1954-60. doi: 10.3892/or.2014.3026. Epub 2014 Feb 18.

PMID:
24549815
7.

Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.

Mu XY, Dong XL, Sun J, Ni YH, Dong Z, Li XL, Sun EL, Yi Z, Li G.

Asian Pac J Cancer Prev. 2014;15(1):69-73.

8.

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ.

J Clin Oncol. 2008 Feb 20;26(6):848-55. doi: 10.1200/JCO.2007.13.8081.

PMID:
18281656
9.

Combined treatment of XIAP-targeting shRNA and celecoxib synergistically inhibits the tumor growth of non‑small cell lung cancer cells in vitro and in vivo.

Zhang H, Li Z, Wang K, Ren P.

Oncol Rep. 2015 Mar;33(3):1079-88. doi: 10.3892/or.2014.3678. Epub 2014 Dec 18.

PMID:
25524805
10.

Nanostructured lipid carrier (NLC) based gel of celecoxib.

Joshi M, Patravale V.

Int J Pharm. 2008 Jan 4;346(1-2):124-32. Epub 2007 Jun 15.

PMID:
17651933
11.

Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2.

Park W, Oh YT, Han JH, Pyo H.

J Exp Clin Cancer Res. 2008 Nov 11;27:66. doi: 10.1186/1756-9966-27-66.

12.

Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.

Liu D, Liu Z, Wang L, Zhang C, Zhang N.

Colloids Surf B Biointerfaces. 2011 Jul 1;85(2):262-9. doi: 10.1016/j.colsurfb.2011.02.038. Epub 2011 Mar 8.

PMID:
21435845
13.

Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.

Gadgeel SM, Wozniak A, Ruckdeschel JC, Heilbrun LK, Venkatramanamoorthy R, Chaplen RA, Kraut MJ, Kalemkerian GP.

J Thorac Oncol. 2008 Nov;3(11):1293-300. doi: 10.1097/JTO.0b013e31818b194e.

14.

Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.

Liu X, Yue P, Zhou Z, Khuri FR, Sun SY.

J Natl Cancer Inst. 2004 Dec 1;96(23):1769-80.

PMID:
15572759
15.

The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M.

Cancer J. 2005 May-Jun;11(3):209-16.

PMID:
16053664
16.

Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.

Shaik MS, Chatterjee A, Jackson T, Singh M.

Int J Cancer. 2006 Jan 15;118(2):396-404.

17.

Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.

Chen L, He Y, Huang H, Liao H, Wei W.

Med Oncol. 2008;25(2):161-71. doi: 10.1007/s12032-007-9015-1. Epub 2008 Jan 3.

PMID:
18172786
18.

Novel strategies for the treatment of lung cancer: modulation of eicosanoids.

Backlund MG, Amann JM, Johnson DH.

J Clin Oncol. 2008 Feb 20;26(6):825-7. doi: 10.1200/JCO.2007.14.9583. No abstract available.

PMID:
18281650
19.

Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA.

Shao Z, Shao J, Tan B, Guan S, Liu Z, Zhao Z, He F, Zhao J.

Int J Nanomedicine. 2015 Feb 11;10:1223-33. doi: 10.2147/IJN.S77837. eCollection 2015.

20.

Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.

Nugent FW, Mertens WC, Graziano S, Levitan N, Collea R, Gajra A, Marshall J, McCann J.

Lung Cancer. 2005 May;48(2):267-73.

PMID:
15829328

Supplemental Content

Support Center